DK2984085T3 - Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme - Google Patents
Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme Download PDFInfo
- Publication number
- DK2984085T3 DK2984085T3 DK14782950.1T DK14782950T DK2984085T3 DK 2984085 T3 DK2984085 T3 DK 2984085T3 DK 14782950 T DK14782950 T DK 14782950T DK 2984085 T3 DK2984085 T3 DK 2984085T3
- Authority
- DK
- Denmark
- Prior art keywords
- modified
- polymer conjugated
- metap2 inhibitors
- fumagillol
- obese
- Prior art date
Links
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 title 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 title 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 title 1
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810468P | 2013-04-10 | 2013-04-10 | |
| US201461925918P | 2014-01-10 | 2014-01-10 | |
| PCT/US2014/033476 WO2014169026A1 (en) | 2013-04-10 | 2014-04-09 | Metap2 inhibitors and methods of treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2984085T3 true DK2984085T3 (da) | 2019-10-21 |
Family
ID=51686946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14782950.1T DK2984085T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme |
| DK19185831.5T DK3574922T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19185831.5T DK3574922T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9173956B2 (enExample) |
| EP (2) | EP3574922B1 (enExample) |
| JP (5) | JP6420314B2 (enExample) |
| CN (2) | CN105431426A (enExample) |
| AU (1) | AU2014250983B2 (enExample) |
| BR (1) | BR112015025892A2 (enExample) |
| CA (1) | CA2908993C (enExample) |
| DK (2) | DK2984085T3 (enExample) |
| EA (1) | EA033912B1 (enExample) |
| ES (2) | ES2749746T3 (enExample) |
| MX (2) | MX371095B (enExample) |
| WO (1) | WO2014169026A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| EP3858385B1 (en) | 2010-05-25 | 2024-09-11 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| MX371095B (es) * | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| CN106432255A (zh) * | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| CN108290853B (zh) * | 2015-12-10 | 2022-05-31 | 辛德弗雷克斯公司 | 烟曲霉醇衍生物及其多晶型物 |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| EP3870231A1 (en) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| CN114656371B (zh) * | 2020-09-14 | 2024-03-12 | 广州药本君安医药科技股份有限公司 | 1,4-环己二胺桥连化合物及在制备治疗糖代谢紊乱疾病的药物中的应用 |
| CA3252252A1 (en) * | 2022-02-16 | 2023-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | METAP2 INHIBITORS AND THEIR USES |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) * | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| AU9376998A (en) * | 1997-09-02 | 1999-03-22 | Johns Hopkins University School Of Medicine, The | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| AU3352799A (en) | 1997-10-31 | 1999-08-23 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| EP1155702A4 (en) | 1998-10-30 | 2004-12-15 | Daiichi Seiyaku Co | DDS CONNECTIONS AND TEST METHODS |
| WO2001018080A1 (en) | 1999-09-08 | 2001-03-15 | School Of Pharmacy, University Of London | Uniform molecular weight polymers |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US20070161570A1 (en) * | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| WO2003070173A2 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2003230852B2 (en) | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040228831A1 (en) * | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| WO2006080591A1 (en) * | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
| WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| WO2009003110A2 (en) | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| WO2009036108A1 (en) * | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) * | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| NZ585547A (en) | 2007-11-28 | 2012-12-21 | Mersana Therapeutics Inc | Biocompatible biodegradable fumagillin analog conjugates |
| CN102105156B (zh) | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065877A2 (en) * | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| TWI373345B (en) * | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| WO2011127304A2 (en) * | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| EP3858385B1 (en) | 2010-05-25 | 2024-09-11 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| EP2575887A4 (en) * | 2010-05-25 | 2015-01-14 | SynDevRX | CONJUGATES OF OPTIMIZED MEDICINES |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| CA2819251A1 (en) * | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| JP5876513B2 (ja) * | 2011-03-08 | 2016-03-02 | ザフゲン，インコーポレイテッド | オキサスピロ［２．５］オクタン誘導体および類似体 |
| MX371095B (es) | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| CN108290853B (zh) | 2015-12-10 | 2022-05-31 | 辛德弗雷克斯公司 | 烟曲霉醇衍生物及其多晶型物 |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
-
2014
- 2014-04-09 MX MX2015014329A patent/MX371095B/es active IP Right Grant
- 2014-04-09 EP EP19185831.5A patent/EP3574922B1/en active Active
- 2014-04-09 EP EP14782950.1A patent/EP2984085B1/en active Active
- 2014-04-09 CA CA2908993A patent/CA2908993C/en active Active
- 2014-04-09 EA EA201591943A patent/EA033912B1/ru unknown
- 2014-04-09 AU AU2014250983A patent/AU2014250983B2/en active Active
- 2014-04-09 CN CN201480032972.7A patent/CN105431426A/zh active Pending
- 2014-04-09 US US14/248,787 patent/US9173956B2/en active Active
- 2014-04-09 DK DK14782950.1T patent/DK2984085T3/da active
- 2014-04-09 ES ES14782950T patent/ES2749746T3/es active Active
- 2014-04-09 ES ES19185831T patent/ES2902082T3/es active Active
- 2014-04-09 DK DK19185831.5T patent/DK3574922T3/da active
- 2014-04-09 BR BR112015025892A patent/BR112015025892A2/pt not_active Application Discontinuation
- 2014-04-09 MX MX2020000562A patent/MX386958B/es unknown
- 2014-04-09 JP JP2016507631A patent/JP6420314B2/ja active Active
- 2014-04-09 WO PCT/US2014/033476 patent/WO2014169026A1/en not_active Ceased
- 2014-04-09 CN CN202011226084.2A patent/CN112494476A/zh active Pending
-
2015
- 2015-09-11 US US14/851,668 patent/US9433600B2/en active Active
-
2016
- 2016-08-02 US US15/226,267 patent/US9757373B2/en active Active
- 2016-08-02 US US15/226,258 patent/US9750737B2/en active Active
-
2017
- 2017-08-01 US US15/665,755 patent/US10010544B2/en active Active
-
2018
- 2018-05-30 US US15/993,059 patent/US10588904B2/en active Active
- 2018-10-11 JP JP2018192578A patent/JP2019023219A/ja active Pending
-
2020
- 2020-01-27 US US16/752,908 patent/US11304944B2/en active Active
-
2021
- 2021-03-17 JP JP2021043481A patent/JP2021091738A/ja active Pending
-
2022
- 2022-02-28 US US17/682,165 patent/US20230048989A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061783A patent/JP7681054B2/ja active Active
-
2025
- 2025-05-09 JP JP2025078682A patent/JP2025109807A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2984085T3 (da) | Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme | |
| DK2984138T3 (da) | Polymersammensætning | |
| EP2975043A4 (en) | Olefin-based polymer | |
| DK2984166T3 (da) | Sammensætninger til behandling af mpsi | |
| BR112016005768A2 (pt) | películas de polímero | |
| DK2875743T3 (da) | Kittel | |
| DE202014011225U8 (de) | Superabsorbierendes Polymer | |
| DK2968833T4 (da) | Kompakte urinkatetre | |
| HUE054627T2 (hu) | Folyékonyanyag-felhordó eszköz | |
| DK3021838T3 (da) | Behandling af fedme | |
| EP2949697A4 (en) | Resin composition | |
| PL3069836T3 (pl) | Urządzenie zakładkowe | |
| DE202014011212U8 (de) | Superabsorberpolymerzusammensetzung | |
| EP2941277A4 (en) | POLYMER DERIVATIVE FROM JUICES | |
| PT2964616T (pt) | Inibidores da neprilisina | |
| EP2877533A4 (en) | SELF-HEALING POLYMERIC COMPOSITIONS | |
| EP2970645A4 (en) | HINGE POLYMER | |
| HUE048637T2 (hu) | Polimerhab | |
| EP3071183C0 (en) | CAVITATION-INDUCING POLYMERIC NANOPARTICLES | |
| PL2981308T3 (pl) | Hemokompatybilne modyfikatory dla usieciowanych materiałów polimerowych | |
| EP2956978A4 (en) | NETWORKED POLYMER ELECTROLYTE | |
| DK3026270T3 (da) | Pumpeindretning | |
| EP3380536A4 (en) | A polymeric composition | |
| EP2993194A4 (en) | multiblock | |
| DK3052102T3 (da) | Sammensætninger til behandling af cancere |